ArticleACG case reports journal2026
Dual Targeted Therapy With Risankizumab and Upadacitinib in Refractory Ulcerative Colitis.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medically refractory acute severe ulcerative colitis (UC) remains a major therapeutic challenge. We describe a 39-year-old woman with multiple prior treatment failures who presented with a steroid-refractory UC flare. Given that she was symptomatic despite high-dose upadacitinib, dual targeted therapy with upadacitinib and risankizumab was initiated. The patient subsequently achieved rapid and sustained clinical remission with complete endoscopic and histologic mucosal healing. No serious adverse events were observed during 10 months of follow-up. This case highlights the potential role of dual targeted therapy with upadacitinib and risankizumab as a treatment strategy for selected patients with refractory severe UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.